During the extended clinically latent period associated with Human Immunodeficiency Virus
(HIV) infection the virus itself is far from latent. This phase of infection generally comes to an …

The introduction of highly active antiretroviral therapy (HAART) as standard of care has
changed the natural history of HIV infection into a manageable chronic disease requiring …

WHO has proposed a public-health approach to antiretroviral therapy (ART) to enable
scaling-up access to treatment for HIV-positive people in develo** countries, recognising …

Purpose The effect of highly active antiretroviral therapy (HAART) on the incidence of non–
AIDS-defining cancers (NADCs) is unclear. Methods We have investigated the occurrence of …

Although it is a standard practice in high-income countries, determination of the human
immunodeficiency virus (HIV) load is not recommended in develo** countries because of …

Objective: To test the utility of the necessity-concerns framework in predicting highly active
antiretroviral therapy (HAART) uptake and adherence. Methods: This was a prospective …

Background: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF),
emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with …

Objective: CD4 cell count changes in therapy-naive patients were investigated during 7
years of highly active antiretroviral therapy (HAART) in an observational cohort. Methods …

Coformulated lopinavir/ritonavir (Kaletra®) is a boosted protease inhibitor (PI) containing
lopinavir and low-dose ritonavir. It is approved for use in combination with other antiretroviral …

A new method using high performance liquid chromatography coupled with electrospray
mass spectrometry (HPLC–MS) was developed and validated, for the quantification of …